XML 61 R41.htm IDEA: XBRL DOCUMENT v2.4.0.6
Stock-Based Compensation - Additional Information (Detail) (USD $)
6 Months Ended 12 Months Ended 6 Months Ended 6 Months Ended
Mar. 31, 2013
Mar. 31, 2012
Sep. 30, 2012
Sep. 30, 2011
Mar. 31, 2013
Calando Pharmaceuticals, Inc. [Member]
Mar. 31, 2011
Calando Pharmaceuticals, Inc. [Member]
Mar. 31, 2013
Arrowhead [Member]
Mar. 31, 2013
2000 Stock Option Plan [Member]
Mar. 31, 2013
2004 Equity Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                  
Shares reserve for issuance               153,200 1,965,860
Options granted and outstanding to purchase 1,989,794   1,910,794 729,096       152,900 1,585,694
Options granted outside of Equity Incentive plans                 251,200
Options granted 79,000   1,229,500           79,000
Stock-based compensation expense $ 750,782 $ 486,152              
Fair value of the options granted 103,293 3,505,912     0 33,690      
Intrinsic value of the options exercised    0              
Pre-tax compensation expense         $ 45,478   $ 3,108,499    
Weighted average period to recognize pre-tax compensation expense         2 years 4 months 24 days   2 years 8 months 12 days    
Dividend yield